CELLMEX is completing a planned modernization of its digital platform and clinical laboratory infrastructure as part of our continued scientific and institutional development.
Our research activities continue, existing patients remain under active physician supervision and continue receiving care under their established clinical protocols, and our medical and scientific teams continue developing patient-specific protocols for participating physicians, clinics and hospital clients.
The updated CELLMEX website is expected to be fully available by mid-September 2026.
Research continues. Patient care continues. Clinical collaboration continues.
CELLMEX integrates scientific research, laboratory manufacturing, quality systems, physician collaboration and responsible clinical services within one regenerative medicine platform.
Our work connects cellular and cell-free biologic technologies with laboratory process development, scientific characterisation, clinical evaluation and structured patient follow-up.
Clinical evaluation, treatment pathways and follow-up.
International ServicesMedical review, scheduling and travel coordination.
Professional InformationScientific resources, protocols and referrals.
Institutional CollaborationProgramme development and clinical partnerships.
Scientific CollaborationLaboratory, translational and clinical research.
Strategic DevelopmentPlatform development and regional growth.
CELLMEX differentiates itself through the integration of clinical medicine, laboratory manufacturing and translational research rather than by promoting a single procedure or product.
Physician-led care begins with diagnosis-specific review and an individual assessment of risks, alternatives and clinical objectives.
Laboratory capability supports cellular processing, process development, preservation, documentation and the controlled preparation of biologic technologies.
Research programmes examine cellular biology, extracellular vesicles, secreted factors, tissue-directed systems and improved laboratory methods.
Regenerative medicine should be developed as a scientific and clinical discipline—not marketed as a collection of procedures.
CELLMEX evaluates each technology according to its biological source, manufacturing process, characterisation, quality controls, clinical evidence and intended application.
Our objective is to create a responsible pathway from scientific inception to laboratory development, physician review and appropriate clinical translation.
Learn About CELLMEX →The identity, composition, evidence level and potential application of each technology must be evaluated independently.
Laboratory-expanded cellular preparations studied for immunomodulatory, paracrine and tissue-support functions.
Defined extracellular-vesicle preparations requiring source, isolation and characterisation review.
Nanoscale vesicle populations evaluated according to particle, marker, purity and functional data.
The broader collection of soluble and vesicular factors released by cultured mesenchymal stromal cells.
Cell-culture media containing biological factors released during controlled culture conditions.
Conditioned-media preparations investigated after reduction or removal of extracellular-vesicle fractions.
Research-stage cellular systems developed under controlled conditions to promote selected lineage-associated characteristics.
Selected immune-cell isolation, activation, expansion and functional-development programmes.
CELLMEX maintains laboratory capability supporting research, cellular processing, biological preparation, preservation and process-development activities.
The laboratory is not presented as a visual accessory to the clinic. It is a core component of the organisation's scientific and manufacturing identity.
A credible regenerative medicine platform must be able to document what biological material was used, how it was processed, how it was stored and how it reached the clinical setting.
Documentation of biological source, collection, transport and acceptance criteria.
Defined culture, processing, concentration, preservation and handling procedures.
Review of identity, viability, sterility-related testing, documentation and deviations.
Connection between source material, laboratory processing, final preparation and clinical use.
Clinical care begins with evaluation of the patient, not selection of a product.
CELLMEX reviews diagnosis, medical history, prior treatment, current therapy, imaging, laboratory data, clinical objectives and relevant risk factors before a biological intervention is considered.
Explore Clinical Programs →Diagnosis-specific physician review and discussion of conventional, supportive and regenerative options.
Evaluation of relevant diagnostic studies, medical reports and previous treatment history.
Individual planning based on medical suitability, evidence, risk and realistic clinical objectives.
Treatment delivery in an appropriate clinical setting by qualified medical professionals.
Structured assessment of safety, tolerability, symptoms, function and continuing medical requirements.
CELLMEX research activities examine scientific mechanisms, laboratory processes, biological identity, formulation, delivery and clinically relevant applications.
Laboratory studies involving cells, culture systems, molecular signals and controlled biological models.
Evaluation of cells, tissues or biological samples outside the body under defined experimental conditions.
Development of improved cellular and cell-free preparations, formulations, processes and final presentations.
Research into controlled culture environments intended to support lineage-associated cellular characteristics.
Physician and institutional cooperation supporting case review, patient follow-up and structured clinical-development programmes.
Controlled transfer of defined scientific or laboratory methods between qualified institutions and professional partners.
CELLMEX distinguishes clinical care, observational follow-up, clinical research and controlled clinical trials rather than using these terms interchangeably.
A treatment programme is not automatically a clinical trial. Formal clinical trials require a defined protocol, appropriate ethical and regulatory review, participant protection, data management and scientific analysis.
CELLMEX may participate in or develop clinical research collaborations where the scientific question, institutional responsibilities, regulatory pathway and patient protections have been appropriately defined.
Physician · Clinical Investigator · Pharmaceutical and Biotechnology Executive
Dr. Patino Cohen directs the clinical and translational development of CELLMEX, integrating regenerative medicine, laboratory operations, physician collaboration and structured patient-care programmes.
His experience involving stem-cell-related work, regenerative medicine and clinical operations dates to 1994. His broader professional work includes speciality pharmaceuticals, biologic technologies, manufacturing, international distribution and regulated-market development.
The leadership philosophy of CELLMEX is based on scientific credibility, responsible innovation, patient safety, laboratory discipline and clear communication of uncertainty.
CELLMEX maintains a scientific library addressing cellular biology, extracellular vesicles, secretome, mechanisms of action, clinical translation and regenerative medicine research.
Publications are presented to support scientific understanding. Inclusion of a paper does not imply that every finding applies directly to a CELLMEX product or clinical programme.
Enter the Medical Publications Library →Peer-reviewed literature concerning MSC biology, immunomodulation and tissue-support mechanisms.
Scientific guidance addressing isolation, terminology, markers, purity and functional assessment.
Research examining the complex biological composition of MSC-derived secreted products.
Scientific and ethical principles governing progression from laboratory work to human clinical application.
Patients receive information concerning clinical programmes, eligibility, medical records, costs, treatment planning and follow-up.
Physicians may request scientific information, discuss patient referrals, review clinical programmes or propose research and institutional collaboration.
Patients, physicians, researchers, clinics, hospitals and strategic collaborators may contact CELLMEX for preliminary information and appropriate departmental referral.